These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. SOME CONSIDERATIONS IN THE SYSTEMIC USE OF FIBRINOLYTIC AGENT. COON WW. Mich Med; 1964 Jul; 63():488-90. PubMed ID: 14182774 [No Abstract] [Full Text] [Related]
9. THE INHIBITION OF TRASYLOL OF FIBRINOLYTIC ACTIVITY ASSOCIATED WITH CARDIOVASCULAR OPERATIONS. TICE DA, WORTH MH, CLAUSS RH, REED GH. Surg Gynecol Obstet; 1964 Jul; 119():71-4. PubMed ID: 14179354 [No Abstract] [Full Text] [Related]
10. Fibrinolysis. II. Absence of antibodies to streptokinase following injection of purified human plasmin in rabbits. TURPINI RA, STEFANINI M, MELE R. Proc Soc Exp Biol Med; 1959 Feb; 100(2):305-7. PubMed ID: 13634121 [No Abstract] [Full Text] [Related]
13. [THE CURRENT STATUS OF FIBRINOLYTIC THERAPY]. KAPPERT A. Med Klin; 1963 Nov 08; 58():1844-6. PubMed ID: 14100260 [No Abstract] [Full Text] [Related]
14. Fibrinolysis. II. Evaluation of enzymatic thrombolysis: Experiments with plasmin preparations in arterial, venous thrombosis. NAHUM LH, KLINE D, FISHBEIN R. Conn Med; 1960 Mar 08; 24():139-46. PubMed ID: 14425837 [No Abstract] [Full Text] [Related]